Jochen K. Lennerz

22.1k citations

222 papers · 10.0k indexed · 5 hit papers · h-index 48

Impact in

Oncology top 0.5%
- Lung Cancer Research Studies
Cancer Research top 1%
- Cancer Genomics and Diagnostics

Papers in

Health Informatics 9
Cancer Research 42
- Cancer Genomics and Diagnostics 37

Co-authors: Jason C. Mills A. John Iafrate Jason M. Doherty William Vermi Anja Fuchs Fabio Facchetti Karel Otero Marco Colonna
Journals: Journal of Clinical Oncology (12 papers)Journal of Thoracic Oncology (11 papers)The Oncologist (8 papers)Oncotarget (8 papers)Journal of Molecular Diagnostics (6 papers)
Partner nations: United States Germany United Kingdom

In The Last Decade

Jochen K. Lennerz

209 papers receiving 9.8k citations

Hit Papers

5 papers align trajectories log scale

Human and mouse trigeminal ganglia cell atlas implicates multiple cell types in migraine 2022 · 97 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 Neuron
2021 Cancer Discovery
2012 Nature
2008 Nature
2008 Nature

Peers

Countries citing papers authored by Jochen K. Lennerz

Since Specialization

Citations

This map shows the geographic impact of Jochen K. Lennerz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jochen K. Lennerz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jochen K. Lennerz more than expected).

Fields of papers citing papers by Jochen K. Lennerz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jochen K. Lennerz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jochen K. Lennerz. The network helps show where Jochen K. Lennerz may publish in the future.

Co-authors

The 25 scholars most cited alongside Jochen K. Lennerz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jochen K. Lennerz Line = papers co-authored together Jochen K. Lennerz links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The Breast Cancer Classifier refines molecular breast cancer classification to delineate the HER2-low subtype npj Breast Cancer ·泰一八田, Ya. R. Maksymenko, L. S. Miller, T Malathi, N D‘Alberto, Hanafi Hadi Susanto, Michael Goldsmith, I Nakayama, AC Jesudoss Prabhakaran, SH Pasterkamp, 包哲钰, Jochen K. Lennerz, 隆行服部, Nikita Kotlov	2025	6
2	Regulation of laboratory-developed tests and in-house in vitro diagnostic medical devices in the United States and the European Union—a comparative overview ESMO Open ·André Kahles, Алиев Тахир Аскерович, 刘新圣, Manuel Salto‐Tellez, Michael Vogeser, Jack Stone, Monika Brüggemann, Jan Budczies, Daniel Kazdal, Roberto Salgado, Peter Schirmacher, Susan E. Peters, Jochen K. Lennerz, Albrecht Stenzinger	2025	0
3	Reproducible Reporting of the Collection and Evaluation of Annotations for Artificial Intelligence Models Modern Pathology ·Отабек Кудратович Алимардонов, B Naresh, Víctor García, Amy Ly, Evangelos Hytopoulos, Weinan Zhang, Matthew G. Hanna, Dieter Peeters, Joel Saltz, Anna Ehinger, Sarah Dudgeon, Xiaoxian Li, Kim Blenman, Weijie Chen, Ursula Green, 박규우, Tony Pan, Jochen K. Lennerz, Roberto Salgado, Brandon D. Gallas	2024	6
4	Compromised Outcomes in Stage IV Non–Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data JCO Oncology Practice ·Jeffrey A. Scott, Jochen K. Lennerz, Melissa L. Johnson, Lucio Gordan, I Wayan Satya Dwiantara, Luca Quagliata, Lauren L. Ritterhouse, Federico Cappuzzo, Brandon Wang, Mei Xue, Anupama Vasudevan, 美保池, Varun Vaidya, K. Kay, W. E. Scott, Hinco J. Gierman, Taghreed A. Wahwah Al-Nashi	2023	28
5	TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis Therapeutic Advances in Medical Oncology ·Arielle J. Medford, Lauren Oshry, Bariş Boyraz, Lesli A. Kiedrowski, N D‘Alberto, T Malathi, Charles S. Dai, Tasos Gogakos, Aleksandra Davidovna Sherfedinova, Rachel O. Abelman, 青木昭子, Jochen K. Lennerz, Laura M. Spring, Beverly Moy, Leif W. Ellisen, Aditya Bardia	2023	5
6	Sensitivity to ALK-Directed Therapy in Osteosarcoma With an Acquired ALK Rearrangement JCO Precision Oncology ·Zehra Ordulu, Taher Al-Fakharany, Wei‐Ting Hung, Yin P. Hung, Judit Simon, Florian J. Fintelmann, Jochen K. Lennerz, Kamila Naxerova, Gregory M. Coté	2023	1
7	Identification of fusions with potential clinical significance in melanoma Modern Pathology ·M. Schlepper, Long P. Le, Valentina Nardi, Sergio Coral, Alexander Farahani, 祐司金岡, Maristela L. Onozato, Ruth K. Foreman, Lyn M. Duncan, Donald P. Lawrence, Jochen K. Lennerz, Dora Dias‐Santagata, Mai P. Hoang	2022	18
8	Developmental Deconvolution for Classification of Cancer Origin Cancer Discovery ·Enrico Moiso, Alexander Farahani, Hetal D. Marble, Henny Dwi Bhakti, Ching-Ching Hsu, Stuart S. Levine, Jochen K. Lennerz, Salil Garg	2022	12
9	RoboCap: Robotic mucus-clearing capsule for enhanced drug delivery in the gastrointestinal tract Science Robotics ·Shriya S. Srinivasan, S. HARBANS, 博文熊澤, Nkanyiso K. Ndlovu, Johannes Kuosmanen, Keiko Ishida, J. A. Jenkins, Sajjad Hossain Talukder, Wiam Abdalla Mohammed Madani, Jochen K. Lennerz, Alison Hayward, Joshua Morimoto, TS.B. KIKEEV, Róbert Langer, Giovanni Traverso	2022	81
10	Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer Clinical Cancer Research ·Neelima Vidula, Andrzej Niemierko, Hans Gade, 张栗辉, Jochen K. Lennerz, A. John Iafrate, Seth A. Wander, Laura M. Spring, Dejan Juric, Steven J. Isakoff, Jerry Younger, Beverly Moy, Leif W. Ellisen, Aditya Bardia	2021	12
11	Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation Cancer Discovery ·Noritaka Tanaka, W. Marston Linehan, Chendi Li, Meagan B. Ryan, Junbing Zhang, Lesli A. Kiedrowski, Alexa Michel, Mohammed U. Syed, Kally Inês Lins, Mustafa Sakhi, Islam Baiev, Dejan Juric, Justin F. Gainor, Samuel J. Klempner, Jochen K. Lennerz, Giulia Siravegna, Liron Bar‐Peled, Aaron N. Hata, Rebecca S. Heist, Ryan B. Corcoran Hit paper breakdown →	2021	302
12	Evolutionary Analysis of Pre- and Post-treatment Molecular Diversity in Rectal Cancer Patients Receiving Neoadjuvant Chemoradiation (CRT) and a KRAS Mutation-targeted Radiosensitizer International Journal of Radiation OncologyBiologyPhysics ·Sophia C. Kamran, Christine E. Eyler, Jochen K. Lennerz, Jennifer Y. Wo, Shiri Shahmoon, Hui Zheng, Darrel R. Borger, Jill N. Allen, David L. Berger, James C. Cusack, 乔桂香, Andrew X. Zhu, Jeffrey W. Clark, Jason A. Efstathiou, Henning Willers, L. Maciejewska, Kevin M. Haigis, Theodore S. Hong	2020	0
13	Clinical Assessment and Validation of a Rapid and Sensitive SARS-CoV-2 Test Using Reverse Transcription Loop-Mediated Isothermal Amplification Without the Need for RNA Extraction Open Forum Infectious Diseases ·Melis N. Anahtar, Graham McGrath, Brian Rabe, Nathan A. Tanner, Benjamin A. White, Jochen K. Lennerz, John A. Branda, Constance L. Cepko, Eric Rosenberg	2020	39
14	Targeted Informatics for Optimal Detection, Characterization, and Quantification of FLT3 Internal Tandem Duplications Across Multiple Next-Generation Sequencing Platforms Journal of Molecular Diagnostics ·Harrison Tsai, Diane Brackett, David Szeto, Ryan P. Frazier, H NIHEI, Phani K. Davineni, Danielle K. Manning, Elizabeth Garcia, Neal I. Lindeman, Long P. Le, Jochen K. Lennerz, Christopher J. Gibson, R. Coleman Lindsley, Annette S. Kim, Valentina Nardi	2020	13
15	COVID-19-neutralizing antibodies predict disease severity and survival Cell ·Wilfredo F. García-Beltrán, Evan C. Lam, Michael G. Astudillo, Diane Yang, Tyler E. Miller, Jared Feldman, Blake M. Hauser, Timothy M. Caradonna, Kiera Clayton, Adam D. Nitido, Mandakolathur R. Murali, Galit Alter, Richelle C. Charles, Anand S. Dighe, John A. Branda, Jochen K. Lennerz, Daniel Lingwood, Aaron G. Schmidt, A. John Iafrate, Alejandro B. Balazs	2020	407
16	Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clinical Cancer Research ·Sophia C. Kamran, Jochen K. Lennerz, Claire A. Margolis, David Liu, Brendan Reardon, Stephanie A. Wankowicz, Emily E. Van Seventer, Adam Tracy, Jennifer Y. Wo, Scott L. Carter, Henning Willers, Ryan B. Corcoran, Theodore S. Hong, Eliezer M. Van Allen	2019	62
17	Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity Clinical Cancer Research ·Ibiayi Dagogo‐Jack, Marguerite Rooney, W. Marston Linehan, Rebecca J. Nagy, Beow Y. Yeap, Harper Hubbeling, Emily Chin, Jennifer Ackil, Anna F. Farago, Aaron N. Hata, Jochen K. Lennerz, Justin F. Gainor, Richard B. Lanman, Alice T. Shaw	2019	112
18	Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer Clinical Cancer Research ·Ibiayi Dagogo‐Jack, Pablo Martínez, Beow Y. Yeap, Chiara Ambrogio, Lorin A. Ferris, Christine Lydon, Tom Nguyen, Nicholas A. Jessop, A. John Iafrate, Bruce E. Johnson, Jochen K. Lennerz, Alice T. Shaw, Mark M. Awad	2018	80
19	MET Amplification in Esophageal Squamous Carcinoma International Journal of Surgical Pathology ·Phillip Michaels, Hayley Robinson, Valentina Nardi, A. John Iafrate, Long P. Le, Jochen K. Lennerz	2018	2
20	Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET -Amplified Esophagogastric Cancer Cancer Discovery ·Eunice L. Kwak, Leanne G. Ahronian, Giulia Siravegna, Benedetta Mussolin, Darrell R. Borger, Jason T. Godfrey, Nicholas A. Jessop, Jeffrey W. Clark, Lawrence S. Blaszkowsky, David P. Ryan, Jochen K. Lennerz, A. John Iafrate, Alberto Bardelli, Theodore S. Hong, Ryan B. Corcoran	2015	138

About Jochen K. Lennerz

Jochen K. Lennerz is a scholar working on Health Informatics, Cancer Research, Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine, having authored 222 papers that have together received 10.0k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (37 papers), Lung Cancer Treatments and Mutations (35 papers), Radiomics and Machine Learning in Medical Imaging (18 papers), Genetic factors in colorectal cancer (14 papers), AI in cancer detection (14 papers), Colorectal Cancer Treatments and Studies (12 papers), Pancreatic and Hepatic Oncology Research (11 papers) and Sarcoma Diagnosis and Treatment (9 papers). The work is most often cited by research in Oncology (2.7k citations), Cancer Research (1.3k citations), Immunology (1.7k citations), Health Informatics (99 citations) and Pathology and Forensic Medicine (1.2k citations). Jochen K. Lennerz has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Jason C. Mills, A. John Iafrate, Jason M. Doherty, William Vermi, Anja Fuchs, Fabio Facchetti, Karel Otero, Marco Colonna, Marina Cella and Karl Meßlinger. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, The Oncologist, Oncotarget and Journal of Molecular Diagnostics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact